Physician profile
Adrian C Buckner
NPI 1437169901
$64,211.41
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $12K · 2021: $20K · 2022: $4,954.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $26,754.07 | 2019-2022 | |
| Allergan, INC. | $12,314.47 | 2019-2020 | |
| Alkermes, INC. | $9,698.31 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $4,880.08 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $3,999.94 | 2019-2022 | |
| Abbvie INC. | $2,124.22 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $1,177.21 | 2019-2022 | |
| Lundbeck LLC | $901.70 | 2019-2022 | |
| Bausch Health US, LLC | $604.67 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $511.09 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $396.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $269.07 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $143.12 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.94 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $87.65 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $74.04 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $70.77 | 2019-2021 | |
| Almatica Pharma LLC | $26.01 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.73 | 2019 | |
| Neuronetics, INC. | $12.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Buckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.